SUNPHARMA's weekly performance was disappointing, with a return of -3.53% and a max drawdown of the same magnitude, indicating a significant decline in value. The stock's volatility was moderate at 15.43%, which is relatively high compared to its peers. Compared to its peers, SUNPHARMA underperformed, with a lower return and Sharpe ratio than DRREDDY and DIVISLAB. The stock's risk profile was moderate to high this week, as reflected in its Sharpe ratio of -1.22.

[Volatility: 15.43%]